Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' BoostrixTM Vaccine Using a New Syringe Presentation in Healthy Adolescents Aged 10-15 Years.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Aug 2012 Planned End Date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.